Befovacimab clinical trials
Also written BAY1093884.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses befovacimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BAY1093884
- 3
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses befovacimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without InhibitorsTerminatedPhase 2BayerNCT03597022Written as Befovacimab (BAY1093884)
- A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe HemophiliaCompletedPhase 1BayerNCT03481946Written as BAY1093884
- Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe HemophiliaWithdrawnPhase 1BayerNCT03996486Written as BAY1093884
- A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without InhibitorsCompletedPhase 1BayerNCT02571569Written as BAY1093884
Codes
What other systems call befovacimab · ClinicalTrials.gg INT015655
- UNII (FDA) 8FFQ0L4R3BBEFOVACIMABOne source FDA
- NCI Thesaurus C171827BefovacimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8FFQ0L4R3B | BEFOVACIMAB | One source FDA |
| NCI Thesaurus | C171827 | Befovacimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.